Comparative efficacy between atorvastatin and rosuvastatin in the prevention of cardiovascular disease recurrence
Entity
UAM. Departamento de Medicina Preventiva y Salud Pública y MicrobiologíaPublisher
BMC (part of Springer Nature)Date
2019-12-11Citation
10.1186/s12944-019-1153-x
Lipids in Health and Disease 18 (2019): 216
ISSN
1476-511XDOI
10.1186/s12944-019-1153-xFunded by
This study was funded by CIBERCV (grant number CB16/11/00451), and Sociedad Española de Arteriosclerosis (SEA 2019)Editor's Version
https://doi.org/10.1186/s12944-019-1153-xSubjects
Rosuvastatin; Atorvastatin; Secondary prevention; High-potent statin; MedicinaRights
© The Author(s). 2019Abstract
Background: There is no randomized clinical trials with recurrence of atherosclerotic cardiovascular disease
(ASCVD) as a major outcome with rosuvastatin. In order to analyze potential differences in the clinical response to
atorvastatin and rosuvastatin in secondary ASCVD prevention, we have analyzed the clinical evolution of those
subjects of the Dyslipemia Registry of the Spanish Society of Arteriosclerosis (SEA) who at the time of inclusion in
the Registry had already suffered an ASCVD.
Methods: This observational, retrospective, multicenter, national study was designed to determine potential
differences between the use of atorvastatin and rosuvastatin in the ASCVD recurrence. Three different follow-up
start-times were performed: time of inclusion in the registry; time of first event if this occurred after 2005, and time
of first event without date restriction.
Results: Baseline characteristics were similar between treatment groups. Among atorvastatin or rosuvastatin users,
89 recurrences of ASCVD were recorded (21.9%), of which 85.4% were coronary. At the inclusion of the subject in
the registry, 345 participants had not suffered a recurrence yet. These 345 subjects accumulated 1050 person-years
in a mean follow-up of 3 years. Event rates were 2.73 (95% CI: 1.63, 4.25) cases/100 person-years and 2.34 (95% CI:
1.17, 4.10) cases/100 person-years in the atorvastatin and rosuvastatin groups, respectively. There were no
statistically significant differences between the two groups independently of the follow-up start-time.
Conclusions: This study does not find differences between high doses of rosuvastatin and atorvastatin in the
recurrence of ASCVD, and supports their use as clinically equivalent in secondary prevention of ASCVD
Files in this item
Google Scholar:Perez-Calahorra, Sofía
-
Laclaustra, Martin
-
Marco-Benedi, Victoria
-
Pinto, Xavier
-
Sánchez-Hernández, Rosa M.
-
Plana, Nùria
-
Ortega, Emilio
-
Fuentes, Francisco
-
Civeira, Fernando
This item appears in the following Collection(s)
Related items
Showing items related by title, author, creator and subject.
-
Type 2 diabetes and cognitive impairment in an older population with overweight or obesity and metabolic syndrome: baseline cross-sectional analysis of the PREDIMED-plus study
Mallorquí-Bagué, Núria; Lozano-Madrid, María; Toledo, Estefanía; Corella, Dolores; Salas-Salvadó, Jordi; Cuenca-Royo, Aida; Vioque, Jesús; Romaguera, Dora; Martínez, J. Alfredo; Wärnberg, Julia; López-Miranda, José; Estruch, Ramón; Bueno-Cavanillas, Aurora; Alonso-Gómez, Ángel; Tur, Josep A.; Tinahones, Francisco J.; Serra-Majem, Lluís; Martín, Vicente; Lapetra, José; Vázquez, Clotilde; Pintó, Xavier; Vidal, Josep; Daimiel, Lidia; Gaforio, José J.; Matía, Pilar; Ros, Emilio; Granero, Roser; Buil-Cosiales, Pilar; Barragán, Rocío; Bulló, Mònica; Castañer, Olga; García-de-la-Hera, Manoli; Yáñez, Aina M.; Abete, Itziar; García-Ríos, Antonio; Ruiz-Canela, Miguel; Díaz-López, Andrés; Jiménez-Murcia, Susana; Martínez-González, Miguel Ángel; De la Torre, Rafael; Fernández-Aranda, Fernando
2018-10-31 -
Long runs of homozygosity are associated with Alzheimer's disease
Moreno-Grau, Sonia; Fernández, María Víctoria; de Rojas, Itziar; García-González, Pablo; Hernández, Isabel; Farias, Fabiana; Budde, John P.; Quintela, Inés; Madrid, Laura; González-Pérez, António; Montrreal, Laura; Alarcón-Martín, Emilio; Alegret, Montserrat; Maronas, Olalla; Pineda, Juan António; Macias, Juan; Marquie, Marta; Valero, Sergi; Benaque, Alba; Clarimon, Jordi; Bullido Gómez-Heras, María Jesús; García-Ribas, Guillermo; Pastor, Pau; Sánchez-Juan, Pascual; Álvarez, Víctoria; Pinol-Ripoll, Gerard; García-Alberca, José Maria; Royo, José Luis; Franco-Macias, Emilio; Mir, Pablo; Calero, Miguel; Medina, Miguel; Rábano, Alberto; Ávila, Jesús; Antúnez, Carmen; Real, Luis Miguel; Orellana, Adelina; Carracedo, Ángel; Sáez, María Eugenia; Tarraga, Lluis; Boada, Merce; Cruchaga, Carlos; Ruiz, Agustín; GR ACE Study groupDEGESCO Consortium; Alzheimer's Dis Neuroimaging Initiative
2021-02-24 -
Oxidized low-density lipoprotein receptor in lymphocytes prevents atherosclerosis and predicts subclinical disease
Tsilingiri, Katerina; Fuente, Hortensia de la; Relaño, Marta; Sánchez-Díaz, Raquel; Rodríguez, Cristina; Crespo, Javier; Sánchez-Cabo, Fátima; Dopazo, Ana; Alonso-Lebrero, José L.; Vara, Alicia; Vázquez, Jesús; Casasnovas, José M.; Alfonso Manterola, Fernando; Ibáñez, Borja; Fuster, Valentín; Martínez-González, José; Martín, Pilar; Sánchez Madrid, Francisco
2019-01-08